Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 561

Similar articles for PubMed (Select 17595888)

2.

Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis.

Giovannoni G, Barbarash O, Casset-Semanaz F, Jaber A, King J, Metz L, Pardo G, Simsarian J, Sørensen PS, Stubinski B; RNF Study Group.

Clin Ther. 2007 Jun;29(6):1128-45.

PMID:
17692727
3.

Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.

O'Farrell AM, van Vliet A, Abou Farha K, Cherrington JM, Campbell DA, Li X, Hanway D, Li J, Guler HP.

Clin Ther. 2007 Aug;29(8):1692-705.

PMID:
17919550
6.

Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.

Lim KS, Kim JR, Choi YJ, Shin KH, Kim KP, Hong JH, Cho JY, Shin HS, Yu KS, Shin SG, Kwon OH, Hwang DM, Kim JA, Jang IJ.

Clin Ther. 2008 Oct;30(10):1817-30. doi: 10.1016/j.clinthera.2008.10.013.

PMID:
19014837
7.

Pharmacokinetics of 8-hour intravenous infusion of NXY-059: a phase I, randomized, double-blind (within dose panels), placebo-controlled study in healthy Chinese volunteers.

Cheng YF, Jiang J, Hu P, Reinholdsson I, Guo W, Asenblad N, Nilsson D.

Clin Ther. 2008 Dec;30(12):2342-53. doi: 10.1016/j.clinthera.2008.12.013.

PMID:
19167593
8.
9.

Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.

Hurwitz BJ, Jeffery D, Arnason B, Bigley K, Coyle P, Goodin D, Kaba S, Kirzinger S, Lynch S, Mandler R, Mikol D, Rammohan K, Sater R, Sriram S, Thrower B, Boateng F, Jakobs P, Wash MB, Bogumil T.

Clin Ther. 2008 Jun;30(6):1102-12. doi: 10.1016/j.clinthera.2008.06.013.

PMID:
18640466
11.

Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes.

Covington P, Christopher R, Davenport M, Fleck P, Mekki QA, Wann ER, Karim A.

Clin Ther. 2008 Mar;30(3):499-512. doi: 10.1016/j.clinthera.2008.03.004.

PMID:
18405788
12.
15.

Pharmacokinetics, bioequivalence, tolerability, and effects on platelet counts of two formulations of anagrelide in healthy volunteers and patients with thrombocythemia associated with chronic myeloproliferation.

Petrides PE, Gisslinger H, Steurer M, Linkesch W, Krumpl G, Schüller A, Widmann R.

Clin Ther. 2009 Feb;31(2):386-98. doi: 10.1016/j.clinthera.2009.02.008.

PMID:
19302911
17.

The Rebif new formulation story: it's not trials and error.

Jaber A, Driebergen R, Giovannoni G, Schellekens H, Simsarian J, Antonelli M.

Drugs R D. 2007;8(6):335-48. Review.

PMID:
17963425
18.
19.

Efficacy and safety of inhaled zanamivir in the prevention of influenza in community-dwelling, high-risk adult and adolescent subjects: a 28-day, multicenter, randomized, double-blind, placebo-controlled trial.

LaForce C, Man CY, Henderson FW, McElhaney JE, Hampel FC Jr, Bettis R, Kudule L, Harris J, Yates P, Tisdale M, Webster A.

Clin Ther. 2007 Aug;29(8):1579-90; discussion 1577-8.

PMID:
17919541
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk